ABSTRACT
Androgen deprivation therapy (ADT) is the standard of care for treatment of nonresectable prostate cancer. Despite high treatment efficiency, most patients ultimately develop lethal castration-resistant prostate cancer (CRPC). In this study, we performed a comparative proteomic analysis of three in vivo, androgen receptor (AR)-responsive orthograft models of matched hormone-naïve prostate cancer and CRPC. Differential proteomic analysis revealed that distinct molecular mechanisms, including amino acid (AA) and fatty acid metabolism, are involved in the response to ADT in the different models. Despite this heterogeneity, Schlafen family member 5 (SLFN5) was identified as an AR-regulated protein in CRPC. SLFN5 expression was high in CRPC tumors and correlated with poor patient outcome. In vivo, SLFN5 depletion strongly impaired tumor growth in castrated conditions. Mechanistically, SLFN5 interacted with ATF4 and regulated the expression of LAT1, an essential AA transporter. Consequently, SLFN5 depletion in CRPC cells decreased intracellular levels of essential AA and impaired mTORC1 signaling in a LAT1-dependent manner. These results confirm that these orthograft models recapitulate the high degree of heterogeneity observed in patients with CRPC and further highlight SLFN5 as a clinically relevant target for CRPC. SIGNIFICANCE: This study identifies SLFN5 as a novel regulator of the LAT1 amino acid transporter and an essential contributor to mTORC1 activity in castration-resistant prostate cancer.
Subject(s)
Biomarkers, Tumor/metabolism , Cell Cycle Proteins/metabolism , Gene Expression Regulation, Neoplastic , Large Neutral Amino Acid-Transporter 1/metabolism , Prostatic Neoplasms, Castration-Resistant/pathology , TOR Serine-Threonine Kinases/metabolism , Activating Transcription Factor 4/genetics , Activating Transcription Factor 4/metabolism , Animals , Apoptosis , Biomarkers, Tumor/genetics , Cell Cycle Proteins/genetics , Cell Proliferation , Humans , Large Neutral Amino Acid-Transporter 1/genetics , Male , Mechanistic Target of Rapamycin Complex 1/genetics , Mechanistic Target of Rapamycin Complex 1/metabolism , Metabolome , Mice , Mice, Nude , Prognosis , Prostatic Neoplasms, Castration-Resistant/genetics , Prostatic Neoplasms, Castration-Resistant/metabolism , Proteome , Survival Rate , TOR Serine-Threonine Kinases/genetics , Transcriptome , Tumor Cells, Cultured , Xenograft Model Antitumor AssaysABSTRACT
Peroxisome Proliferator-Activated Receptor Gamma (PPARG) is one of the three members of the PPAR family of transcription factors. Besides its roles in adipocyte differentiation and lipid metabolism, we recently demonstrated an association between PPARG and metastasis in prostate cancer. In this study a functional effect of PPARG on AKT serine/threonine kinase 3 (AKT3), which ultimately results in a more aggressive disease phenotype was identified. AKT3 has previously been shown to regulate PPARG co-activator 1 alpha (PGC1α) localisation and function through its action on chromosome maintenance region 1 (CRM1). AKT3 promotes PGC1α localisation to the nucleus through its inhibitory effects on CRM1, a known nuclear export protein. Collectively our results demonstrate how PPARG over-expression drives an increase in AKT3 levels, which in turn has the downstream effect of increasing PGC1α localisation within the nucleus, driving mitochondrial biogenesis. Furthermore, this increase in mitochondrial mass provides higher energetic output in the form of elevated ATP levels which may fuel the progression of the tumour cell through epithelial to mesenchymal transition (EMT) and ultimately metastasis.
Subject(s)
PPAR gamma/genetics , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/genetics , Prostatic Neoplasms/genetics , Proto-Oncogene Proteins c-akt/genetics , Animals , Cell Line, Tumor , Epithelial-Mesenchymal Transition/genetics , Gene Expression Regulation, Neoplastic , Humans , Karyopherins/genetics , Lipid Metabolism/genetics , Male , Mice , Mitochondria/genetics , Organelle Biogenesis , Prostatic Neoplasms/pathology , Receptors, Cytoplasmic and Nuclear/genetics , Exportin 1 ProteinABSTRACT
The signalling pathways underpinning cell growth and invasion use overlapping components, yet how mutually exclusive cellular responses occur is unclear. Here, we report development of 3-Dimensional culture analyses to separately quantify growth and invasion. We identify that alternate variants of IQSEC1, an ARF GTPase Exchange Factor, act as switches to promote invasion over growth by controlling phosphoinositide metabolism. All IQSEC1 variants activate ARF5- and ARF6-dependent PIP5-kinase to promote PI(3,4,5)P3-AKT signalling and growth. In contrast, select pro-invasive IQSEC1 variants promote PI(3,4,5)P3 production to form invasion-driving protrusions. Inhibition of IQSEC1 attenuates invasion in vitro and metastasis in vivo. Induction of pro-invasive IQSEC1 variants and elevated IQSEC1 expression occurs in a number of tumour types and is associated with higher-grade metastatic cancer, activation of PI(3,4,5)P3 signalling, and predicts long-term poor outcome across multiple cancers. IQSEC1-regulated phosphoinositide metabolism therefore is a switch to induce invasion over growth in response to the same external signal. Targeting IQSEC1 as the central regulator of this switch may represent a therapeutic vulnerability to stop metastasis.
Subject(s)
Guanine Nucleotide Exchange Factors/metabolism , Neoplasm Metastasis , Phosphatidylinositols/metabolism , Signal Transduction , ADP-Ribosylation Factor 6 , ADP-Ribosylation Factors/metabolism , Animals , Carcinogenesis/genetics , Carcinogenesis/metabolism , Cell Line, Tumor , Guanine Nucleotide Exchange Factors/genetics , Heterografts , Humans , Low Density Lipoprotein Receptor-Related Protein-1/metabolism , Male , Mice , Mice, Nude , Neoplasm Metastasis/genetics , Neoplasms/metabolism , Proto-Oncogene Proteins c-akt/metabolismABSTRACT
Epstein-Barr virus (EBV), which is ubiquitous in the adult population, is causally associated with human malignancies. Like many infectious agents, EBV has evolved strategies to block host cell death, including through expression of viral homologues of cellular BCL-2 pro-survival proteins (vBCL-2s), such as BHRF1. Small molecule inhibitors of the cellular pro-survival BCL-2 family proteins, termed 'BH3-mimetics', have entered clinical trials for blood cancers with the BCL-2 inhibitor venetoclax already approved for treatment of therapy refractory chronic lymphocytic leukaemia and acute myeloid leukaemia in the elderly. The generation of BH3-mimetics that could specifically target vBCL-2 proteins may be an attractive therapeutic option for virus-associated cancers, since these drugs would be expected to only kill virally infected cells with only minimal side effects on normal healthy tissues. To achieve this, a better understanding of the contribution of vBCL-2 proteins to tumorigenesis and insights into their biochemical functions is needed. In the context of Burkitt lymphoma (BL), BHRF1 expression conferred strong resistance to diverse apoptotic stimuli. Furthermore, BHRF1 expression in mouse haematopoietic stem and progenitor cells accelerated MYC-induced lymphoma development in a model of BL. BHRF1 interacts with the cellular pro-apoptotic BCL-2 proteins, BIM, BID, PUMA and BAK, but its capability to inhibit apoptosis could not be mapped solely to one of these interactions, suggesting plasticity is a key feature of BHRF1. Site-directed mutagenesis revealed a site in BHRF1 that was critical for its interaction with PUMA and blocking DNA-damage-induced apoptosis, identifying a potentially therapeutically targetable vulnerability in BHRF1.
Subject(s)
Apoptosis , Burkitt Lymphoma/pathology , Carcinogenesis/pathology , Drug Resistance, Neoplasm , Proto-Oncogene Proteins c-bcl-2/chemistry , Sequence Homology, Amino Acid , Viral Proteins/metabolism , Animals , Apoptosis/genetics , Bcl-2-Like Protein 11/metabolism , Burkitt Lymphoma/virology , Cell Death , Cell Line, Tumor , Cytoprotection , Drug Resistance, Neoplasm/genetics , Humans , Loss of Function Mutation , Mice , Mice, Inbred C57BL , Protein Binding , Proto-Oncogene Proteins c-myc/metabolism , Viral Proteins/chemistry , Viral Proteins/genetics , Virus LatencyABSTRACT
The incorporation of transition metal catalysts to the bioorthogonal toolbox has opened the possibility of producing supra-stoichiometric amounts of xenobiotics in living systems in a non-enzymatic fashion. For medical use, such metals could be embedded in implantable devices (i.e. heterogeneous catalyst) to "synthesize" drugs in desired locations (e.g. in a tumour) with high specificity and for extended periods of time, overcoming the useful life limitations of current local therapy modalities directed to specific organ sites (e.g. brachytherapy, controlled release systems). To translate this approach into a bona fide therapeutic option, it is essential to develop clinically-accessible implantation procedures and to understand and validate the activation process in relevant preclinical models. Herein we report the development of a novel Pd-activatable precursor of the red-fluorescent drug doxorubicin and Pd devices of optimized size and activity. Screening in state-of-the-art cancer models provided fundamental insights into the insertion protocols, safety and stability of the devices and into the prodrug distribution profile before and after activation.
ABSTRACT
Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.
Subject(s)
Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Models, Biological , Myeloid Cell Leukemia Sequence 1 Protein/antagonists & inhibitors , Neoplasms/drug therapy , Neoplasms/pathology , Pyrimidines/pharmacology , Pyrimidines/therapeutic use , Thiophenes/pharmacology , Thiophenes/therapeutic use , Animals , Antineoplastic Agents/administration & dosage , Apoptosis/drug effects , Cell Line, Tumor , Female , Humans , Leukemia/drug therapy , Leukemia/metabolism , Leukemia/pathology , Lymphoma/drug therapy , Lymphoma/metabolism , Lymphoma/pathology , Male , Mice , Models, Molecular , Multiple Myeloma/drug therapy , Multiple Myeloma/metabolism , Multiple Myeloma/pathology , Myeloid Cell Leukemia Sequence 1 Protein/chemistry , Myeloid Cell Leukemia Sequence 1 Protein/metabolism , Neoplasms/metabolism , Pyrimidines/administration & dosage , Thiophenes/administration & dosage , Xenograft Model Antitumor Assays , bcl-2 Homologous Antagonist-Killer Protein/metabolism , bcl-2-Associated X Protein/metabolismABSTRACT
BACKGROUND: Lipids are best known for their fundamental role in forming biological membranes and as intracellular signalling molecules. Interactions between proteins and lipids are central to nearly every cellular process yet these crucial relationships often go overlooked. Changes or switches in the lipid profile of a cell drastically affects cellular metabolism and signal transduction. In relationship to cancer, upregulation of lipid metabolism is often observed during the early stages of neoplasia and is a recognised hallmark of many types of cancer. METHODS: We performed a comprehensive review of the literature using PubMed regarding lipid metabolism in cancer and the importance of protein-lipid interactions in the function of mitochondria. RESULTS: An increase in the basal rate of de novo lipogenesis generates a substantial rise in the saturated fatty acid content of cellular membranes. The ensuing alteration in the acyl chain profile of phospholipids has severe consequences on the function of organelles and membrane-bound proteins, and result in a host of pathologies including the cardiac disorder Barth Syndrome. CONCLUSIONS: Although increased lipogenesis is specifically selected for during cellular transformation it remains unclear if it confers an advantage for survival or is a byproduct of more global changes in cellular metabolism. We discuss the current data regarding the potential of targeting the lipogenic switch as a cancer therapy. In addition, we describe the importance of mitochondrial phospholipid composition during a number mitochondria-driven events observed to have roles in cancer. We specifically highlight the function of cardiolipin in maintaining mitochondrial structure, regulating mitochondrial dynamics and bioenergetics as well as its contributions to mitophagy/autophagy and apoptosis.
Subject(s)
Cell Membrane/metabolism , Cell Physiological Phenomena , Lipid Metabolism/physiology , Phospholipids/metabolism , HumansABSTRACT
A mutation in the Drosophila gene technical knockout (tko(25t)), encoding mitoribosomal protein S12, phenocopies human mitochondrial disease. We isolated three spontaneous X-dominant suppressors of tko(25t) (designated Weeble), exhibiting almost wild-type phenotype and containing overlapping segmental duplications including the mutant allele, plus a second mitoribosomal protein gene, mRpL14. Ectopic, expressed copies of tko(25t) and mRpL14 conferred no phenotypic suppression. When placed over a null allele of tko, Weeble retained the mutant phenotype, even in the presence of additional transgenic copies of tko(25t). Increased mutant gene dosage can thus compensate the mutant phenotype, but only when located in its normal chromosomal context.